Work

Phase 2 study of response-guided neoadjuvant sacituzumab govitecan (IMMU-132) in patients with localized triple-negative breast cancer: Results from the NeoSTAR trial.

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.512

Authors: Laura Spring, Sara M. Tolaney, Neelam Vijay Desai, Geoffrey Fell, Lorenzo Trippa, Amy H. Comander, Therese Marie Mulvey, Shannon McLaughlin, Phoebe Ryan, Aron S. Rosenstock, Ana Christina Garrido-Castro, Filipa Lynce, Beverly Moy, Steven J. Isakoff, Nadine M. Tung, Elizabeth A. Mittendorf, Leif W. Ellisen, Aditya Bardia

Institutions: Massachusetts General Hospital, Dana-Farber Cancer Institute, Beth Israel Deaconess Medical Center, Dana-Farber Brigham Cancer Center, Harvard University

Language: English

Topic: Breast Cancer Treatment Studies

Subfield: Cancer Research

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4281629035

Cites:

Cited by: 34

Related to: 10